BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 35241126)

  • 1. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
    Roca MS; Moccia T; Iannelli F; Testa C; Vitagliano C; Minopoli M; Camerlingo R; De Riso G; De Cecio R; Bruzzese F; Conte M; Altucci L; Di Gennaro E; Avallone A; Leone A; Budillon A
    J Exp Clin Cancer Res; 2022 Mar; 41(1):83. PubMed ID: 35241126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
    Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
    Li L; Li Z; Kong X; Xie D; Jia Z; Jiang W; Cui J; Du Y; Wei D; Huang S; Xie K
    Gastroenterology; 2014 Aug; 147(2):485-97.e18. PubMed ID: 24859161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Domatinostat Targets the FOXM1-Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents.
    Nakagawa-Saito Y; Mitobe Y; Suzuki S; Togashi K; Sugai A; Kitanaka C; Okada M
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
    Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
    Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells.
    Marchand B; Pitarresi JR; Reichert M; Suzuki K; Laczkó D; Rustgi AK
    Oncogene; 2019 May; 38(22):4325-4339. PubMed ID: 30705403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness.
    Li Z; Jia Z; Gao Y; Xie D; Wei D; Cui J; Mishra L; Huang S; Zhang Y; Xie K
    Clin Cancer Res; 2015 Feb; 21(4):844-53. PubMed ID: 25501129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity.
    Zheng Q; Tang J; Aicher A; Bou Kheir T; Sabanovic B; Ananthanarayanan P; Reina C; Chen M; Gu JM; He B; Alcala S; Behrens D; Lawlo RT; Scarpa A; Hidalgo M; Sainz B; Sancho P; Heeschen C
    J Exp Clin Cancer Res; 2023 Nov; 42(1):323. PubMed ID: 38012687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
    Mishra VK; Wegwitz F; Kosinsky RL; Sen M; Baumgartner R; Wulff T; Siveke JT; Schildhaus HU; Najafova Z; Kari V; Kohlhof H; Hessmann E; Johnsen SA
    Nucleic Acids Res; 2017 Jun; 45(11):6334-6349. PubMed ID: 28369619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
    Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
    Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma.
    Zhang X; Zegar T; Weiser T; Hamdan FH; Berger BT; Lucas R; Balourdas DI; Ladigan S; Cheung PF; Liffers ST; Trajkovic-Arsic M; Scheffler B; Joerger AC; Hahn SA; Johnsen SA; Knapp S; Siveke JT
    Int J Cancer; 2020 Nov; 147(10):2847-2861. PubMed ID: 32599645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
    Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
    J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
    Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
    Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
    Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
    J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. USP5 promotes tumorigenesis and progression of pancreatic cancer by stabilizing FoxM1 protein.
    Li XY; Wu HY; Mao XF; Jiang LX; Wang YX
    Biochem Biophys Res Commun; 2017 Oct; 492(1):48-54. PubMed ID: 28807830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered histone acetylation patterns in pancreatic cancer cell lines induce subtype‑specific transcriptomic and phenotypical changes.
    Zhou Q; Pichlmeier S; Denz AM; Schreiner N; Straub T; Benitz S; Wolff J; Fahr L; Del Socorro Escobar Lopez M; Kleeff J; Mayerle J; Mahajan UM; Regel I
    Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38240084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
    She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
    J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
    Watanabe S; Shimada S; Akiyama Y; Ishikawa Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
    Int J Cancer; 2019 Jul; 145(1):192-205. PubMed ID: 30556125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mir-320b Inhibits Pancreatic Cancer Cell Proliferation by Targeting FOXM1.
    Jingyang Z; Jinhui C; Lu X; Weizhong Y; Yunjiu L; Haihong W; Wuyuan Z
    Curr Pharm Biotechnol; 2021; 22(8):1106-1113. PubMed ID: 32942974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.